Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy

Recent studies suggest that thiazolidinediones ameliorate diabetic nephropathy (DN) independently of their effect on hyperglycemia. In the current study, we confirm and extend these findings by showing that rosiglitazone treatment prevented the development of DN and reversed multiple markers of oxid...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Zhang, Hongyu, Saha, Jharna, Byun, Jaeman, Schin, MaryLee, Lorenz, Matthew, Kennedy, Robert T., Kretzler, Matthias, Feldman, Eva L., Pennathur, Subramaniam, Brosius, Frank C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Physiological Society 2008
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2576144/
https://ncbi.nlm.nih.gov/pubmed/18667486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1152/ajprenal.90208.2008
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak